Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma - Takeaway - MDSpire
Clinical Guidelines
From the Journals

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib im...

Share

  • 1

    LITESPARK-011 trial explores belzutifan plus lenvatinib vs cabozantinib.

  • 2

    Significant progression-free survival benefit observed.

  • 3

    Overall survival analysis trending favorably but not statistically significant yet.

  • 4

    Anemia more common in combination therapy.

  • 5

    Treatment duration longer with the combination.

  • 6

    Shows potential to address unmet clinical needs in post-PD-(L)1 therapy.

  • 7

    Adverse events similar across treatments; supportive evidence from patient-reported outcomes.

Original Source(s)

Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma

  • by Julia Cipriano

  • April 30, 2026

Related Content

What Is the Optimal Setting for T-DXd in Early Breast Cancer? Experts Differ

Trastuzumab deruxtecan (T-DXd) has claimed a large share of the HER2-positive breast cancer landscape, even finding room among tumors previously thought to be HER2-negative. The DESTINY series of tria...

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Accelerating Biopharmaceutical Development with CE-MS

Microfluidic CE-MS interfaces simplifies and streamlines biotherapeutic characterization to reduce turnaround times in bioanalytical labs

  • April 30, 2026

  • 7 min